CSR IN HEALTHCARE

Rare disease treatment therapies for a variety of life-limiting illnesses are under investigation, and a small number of commercial products have successfully obtained regulatory approval. The cost of treatment is high, and clinical studies evaluating safety and efficacy are performed predominately in high-income countries. Low- and Middle-income countries have barriers to access research and product development and here is the need of society to participate in strengthening life care support for rare disease treatment.

Following are rare disease treatment where we support patient treatment via CSR support   

Leber Congenital Amaurosis (Eye Disorder) 

Sickle cell anemia (SCA)  

Hemophilia  

CAR-T cell therapy for leukemia and lymphomas  

CSR Programme– Rare Disease treatment is the area where support is required to care patients and reach new therapies to them at minimal cost. In this regard we have adoption programme for CSR perspective.

"Adopt a patient clinical trial"

Adoption policies – We customize and suggest CSR initiative as per your corporate social responsibility fit. Rare disease drug development as its own goal to setup fast track research trials. With engagement of multiple corporate houses through their CSR goals, we engage patients who needs immediate relief with the existing rare disease conditions.

Service profiles -

• Collating Good CSR Practices of Company
• Mapping of Stakeholder-wise areas of interventions
• Business Risk Analysis
• Industry and Sector Review
• Baseline Survey
• Planning for inclusive CSR & sustainable strategy
• Advising on CSR intervention area
• Developing a CSR plan
• Framing CSR policy
• CSR audit for legal and legislative compliances, project and agreement parameters